New combo targets Hard-to-Treat stomach tumors
NCT ID NCT05245968
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a new drug, pimitespib (TAS-116), combined with the standard drug imatinib in people with advanced gastrointestinal stromal tumors (GIST) that have stopped responding to imatinib. The study aims to find the safest dose, check for side effects, and see if the combination can slow tumor growth. About 78 participants will be enrolled across different treatment groups.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pimitespib (TAS-116) and imatinib
What this could lead to
If successful, this combination could offer a new treatment option for people with GIST whose cancer has stopped responding to imatinib alone.
What could go wrong
This is an early Phase 1 trial with a small number of participants, so it is not yet clear if the combination is safe or effective. Side effects from the drugs may also limit their use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL STROMAL TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alfred Health
Melbourne, Australia
-
Beijing Cancer Hospital
Beijing, China
-
Flinders Medical Center
Adelaide, Australia
-
Fudan University, Shanghai Cancer Center
Shanghai, China
-
Hokkaido University Hospital
Hokkaido, Japan
-
Kaohsiung Medical University Hospital
Kaohsiung City, Taiwan
-
Kumamoto University Hospital
Kumamoto, Japan
-
Linkou Chang Gung Memorial Hospital
Linkou District, Taiwan
-
National Cancer Center Hospital
Tokyo, Japan
-
National Cancer Center Hospital East
Chiba, Japan
-
National University Cancer Institute
Singapore, Singapore
-
Osaka University Hospital
Osaka, Japan
-
Taipei Veterans General Hospital
Taipei, Taiwan
-
The Cancer Institute Hospital of JFCR
Tokyo, Japan